The Oncology Institute, Inc. $TOI Shares Bought by Renaissance Technologies LLC

Posted by Stanley Muller on Aug 10th, 2026

Renaissance Technologies LLC grew its position in shares of The Oncology Institute, Inc. (NASDAQ:TOI – Free Report) by 25.1% during the 1st quarter, HoldingsChannel.com reports. The firm owned 902,809 shares of the company’s stock after buying an additional 180,909 shares during the quarter. Renaissance Technologies LLC’s holdings in Oncology Institute were worth $2,772,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. GatePass Capital LLC acquired a new stake in shares of Oncology Institute in the 4th quarter valued at about $1,282,000. Josh Arnold Investment Consultant LLC increased its position in Oncology Institute by 1,104.3% during the fourth quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company’s stock worth $8,757,000 after buying an additional 2,255,559 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Oncology Institute by 169.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 419,423 shares of the company’s stock valued at $1,288,000 after buying an additional 263,699 shares during the last quarter. T3 Companies LLC purchased a new stake in Oncology Institute in the fourth quarter valued at approximately $716,000. Finally, CenterBook Partners LP boosted its holdings in shares of Oncology Institute by 12.0% in the fourth quarter. CenterBook Partners LP now owns 3,029,312 shares of the company’s stock valued at $10,784,000 after acquiring an additional 324,662 shares during the period. Institutional investors and hedge funds own 36.86% of the company’s stock.

Analyst Upgrades and Downgrades

TOI has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a report on Friday, July 17th. Needham & Company LLC increased their price target on shares of Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Lake Street Capital started coverage on shares of Oncology Institute in a research report on Monday, July 6th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, BTIG Research lifted their price objective on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Oncology Institute has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Read Our Latest Research Report on TOI

Oncology Institute Stock Up 1.1%

Shares of NASDAQ:TOI opened at $5.19 on Monday. The firm’s 50-day simple moving average is $5.23 and its 200-day simple moving average is $3.97. The Oncology Institute, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $6.67. The company has a market cap of $512.58 million, a price-to-earnings ratio of -14.02 and a beta of 0.39.

Oncology Institute (NASDAQ:TOI – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $161.28 million during the quarter, compared to analyst estimates of $155.28 million. On average, research analysts forecast that The Oncology Institute, Inc. will post -0.18 EPS for the current year.

Insider Activity at Oncology Institute

In related news, insider Yale Podnos sold 23,451 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $5.38, for a total value of $126,166.38. Following the sale, the insider owned 259,527 shares in the company, valued at $1,396,255.26. This represents a 8.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 18,000 shares of the company’s stock in a transaction dated Tuesday, July 21st. The stock was purchased at an average price of $5.27 per share, with a total value of $94,860.00. Following the transaction, the insider owned 10,648,858 shares of the company’s stock, valued at approximately $56,119,481.66. This represents a 0.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 131,500 shares of company stock worth $609,265 in the last three months. Corporate insiders own 4.40% of the company’s stock.

Oncology Institute Profile

(Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.